RIGL
Rigel Pharmaceuticals
Halal Rating :
Last Price
$20.14
Last updated:
Market Cap
-
7D Change
17.71%
1 Year Change
1461.24%
Company Overview
Industries
Exchange
Next Earnings Date
Rigel Pharmaceuticals is a biotechnology company focused on developing drugs for various hematologic disorders, cancer, and rare immune diseases. Their primary commercial product is TAVALISSE® (fostamatinib disodium hexahydrate), which is approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The company generates revenue primarily through product sales and collaborative agreements.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $55.31m | $43.31m | - | $2.06m | 0.00% | 4.76% |
| June 30, 2024 | $36.84m | $38.42m | - | $2.03m | 0.00% | 5.28% |
| March 31, 2024 | $29.53m | $38.37m | - | $1.87m | 0.00% | 4.88% |
Company Impact
Help us evaluate Rigel Pharmaceuticals's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.